Aspirin-another caloric-restriction mimetic

Abstract

The capacity of cells and organisms to sustain, and to eventually adapt to, environmental and genetic insults declines with age. Because macroautophagy/autophagy is regarded as one of the major determinants of cellular fitness in vitro and in vivo, maneuvers that aim at promoting autophagy may slow down aging and promote health span. Caloric restriction (CR), a reduction in caloric intake without malnutrition, efficiently counteracts aging-associated features, yet is difficult to be applied to humans. Caloric-restriction mimetics (CRMs) are pharmacological agents that recapitulate the main biochemical properties of CR, namely a global reduction of protein acetylation and the induction of autophagy. We found that the ancient drug aspirin and its active metabolite salicylate stimulate autophagic flux by virtue of their inhibitory action on acetyltransferase EP300. The inhibition of EP300 results from a direct competition between salicylate and acetyl coenzyme A for binding to the catalytic domain of the enzyme. This mode of action appears to be conserved across evolution as it accounts for the induction of autophagy by aspirin in various mouse models and in the nematode Caenorhabditis elegans. In sum, aspirin acts as a CRM.

Keywords: AMPK; Acetylation; aging; autophagy; fasting; inflammation; longevity; mitophagy; salicylate.

Figure 1.

Comparison of aspirin with other caloric-restriction mimetics. (A). Caloric-restriction mimetics may directly inhibit acetyltransferases, deplete acetyl coenzyme A (AcCoA) or activate deacetylases to stimulate protein deacetylation and consequent autophagy induction. (B) Salicylate generated from its prodrug, aspirin, directly inhibits the acetyltransferase activity of EP300, thus acting as a class I caloric-restriction mimetic to induce protein deacetylation and autophagy.